Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

2, 2010, Anadys will present additional data from the Phase II combination study showing that the addition of ANA598 to SOC conferred benefit independent of a patient's IL-28B genotype. In patients with the IL-28B genotype most responsive to SOC (referred to as CC), ANA598 accelerated the rate of achieving undetectable levels of virus, with 82% of patients who received ANA598 plus SOC achieving undetectable levels by week 4, compared to 27% of patients who received placebo plus SOC.  In patients with IL-28B genotypes less responsive to SOC (referred to as CT and TT, or collectively non-CC), ANA598 both accelerated the rate of achieving undetectable levels of virus and increased the percentage of patients with undetectable levels of virus at week 12.  In the non-CC patients, 38% of patients who received ANA598 plus SOC achieved undetectable levels of virus by week 4, compared to 8% of patients who received placebo plus SOC, and 73% of patients who received ANA598 plus SOC achieved undetectable levels of virus at week 12, compared to 47% of patients who received placebo plus SOC.  

Phase II Combination Study

In the ongoing Phase II study, approximately 90 treatment-naive genotype 1 HCV patients have received ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg twice-daily (bid) or 400 mg bid, each with a loading dose of 800 mg bid on day one. After week 12, patients are to continue receiving SOC. Patients who achieved undetectable levels of virus at weeks 4 and 12 were randomized to stop all treatment at week 24 or 48. The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR). Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of v
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 ... of drugs within human and veterinary oncology, has filed ... and Exchange Commission, in connection with the proposed public ... Stock Market. The number of American Depositary Shares, representing ... for the offering have not yet been determined. An ...
(Date:7/7/2015)...  Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing ... and CEO, Chandler D. Robinson MD, MBA, ... Award. The British Council selected one recipient from each ... , and the United States ... who have leveraged their U.K. education in their subsequent ...
(Date:7/7/2015)...   Abide Therapeutics , a developer of ... dosing of the first subject in a Phase ... endocannabinoid system modulator. ABX-1431 was discovered with Abide,s ... drug candidates that target serine hydrolases, a large ... human physiology and disease. "This is ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
... 2011 Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, announced today ... of an additional $50 million of the company,s shares ... authorization, the total amount available for share repurchases by ...
... University of California San Diego Extension Certificate Program in ... seminar from 5 to 7 pm Thursday, December 8 ... The seminar on conducting clinical trials in Latin America, ... but advance registration is required. The certificate ...
Cached Medicine Technology:Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 2Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 3UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 2UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 3
(Date:7/7/2015)... ... 2015 , ... The Immune Deficiency Foundation (IDF) launched a ... its IDF ePHR, an electronic personal health record powered by Get Real Health’s ... their health information, including symptoms, diagnoses, medications, infusions and other critical health data. ...
(Date:7/7/2015)... Michigan (PRWEB) , ... July 07, 2015 , ... ... the heart of Downtown Detroit was the site of the National Baptist Convention ... Wellness Initiative. Focusing on encouraging and promoting the collaboration of churches and their ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri ... whitening treatments. A professional teeth whitening is one of the fastest, easiest ways to ... as they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Purdy as the company’s new Chief Financial Officer, effective July 6th, 2015. Ellen ... in companies ranging from a multi-billion dollar, global chemical company to early and ...
(Date:7/7/2015)... Schaumburg, IL (PRWEB) , ... ... ... Solutions, Inc., a leading provider of unified communication management solutions, has announced ... Solution, Infortel® Select. , This service pack includes a number of enhancements ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Office Practicum Announces new CFO 2Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2
... of Nursing faculty member Rachel Jones has been selected ... for Community Engagement in Research. This award is for ... in part on data from Newark or Northern New ... Provosts Awards for Community Engagement to acknowledge the valuable ...
... For the first time, researchers have,identified structural ... The results of the study, conducted by ... in Charlottesville and The Children,s Hospital,of Philadelphia in ... the Radiological Society of North America (RSNA)., ...
... Can Learn activities help students identify their unique qualities ... while appreciating those ... All Kids Can, in,partnership with Scholastic, announced today the distribution ... inspire students,to discover their own special abilities and qualities and ...
... University of Pennsylvania School of Medicine and other study ... a non-invasive technique that excites neurons in the brain ... a safe and effective, non-drug treatment with minimal side ... other treatment options without benefit. , This ...
... Women who live in urban areas have denser breasts, ... to a study presented today at the annual meeting ... living in cities need to pay more attention to ... F.R.C.S., F.R.C.R., director of The London Breast Institute at ...
... New Haven, Conn. Bioengineers at Yale and Cornell ... and remains at the site of brain tumors ... according to a report in the November-December issue of ... increase treatment distances to more than a centimeter, which ...
Cached Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Novel MRI Technique Shows Secondhand Smoke Damages Lungs 2Health News:Novel MRI Technique Shows Secondhand Smoke Damages Lungs 3Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 2Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 3Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:City-dwelling women at greater risk for breast cancer 2Health News:New method of drug delivery more effective at reaching brain tumors 2
Picofluor™ Fluorometer is a lightweight, inexpensive, handheld fluorometer, configured for the fluorescent probes commonly used for nucleic acid and protein quantitation....
... FLUORAT®-02-PANORAMA spectrofluorometer ... sophisticated instrument among ... It is intended ... chromatographic analysis, and ...
Inquire...
Inquire...
Medicine Products: